ECRONICON OPEN ACCESS

EC PULMONOLOGY AND RESPIRATORY MEDICINE

Mini Review

Remission in Asthma: Current Scenario

Mohankumar Thekkinkattil*

Senior Consultant Pulmonologist, Department of Pulmonology, Critical Care and Sleep Medicine, OneCare Medical Center, Coimbatore, Tamilnadu, India

***Corresponding Author:** Mohankumar Thekkinkattil, Senior Consultant Pulmonologist, Department of Pulmonology, Critical Care and Sleep Medicine, OneCare Medical Center, Coimbatore, Tamilnadu, India.

Received: July 30, 2024; **Published:** September 09, 2024

Abstract

Asthma, a chronic inflammatory disease of the airways, affects millions globally. While traditionally managed with long-term medication, the concept of remission in asthma has garnered increasing attention. This article reviews the current understanding of asthma remission, including definitions, mechanisms, predictors, and the implications for clinical practice.

Keywords: *Asthma Remission; Predictors of Remission of Asthma*

Introduction

Asthma remission, characterized by the absence of symptoms and normalization of lung function without ongoing medication, remains an elusive goal for many patients. Despite advancements in treatment, the pathways and predictors of remission are not fully understood. This article aims to provide an in-depth analysis of asthma remission, examining current definitions, underlying mechanisms, predictors, and the impact on clinical management [1-3].

Definitions and criteria

Asthma remission can be defined both clinically and biologically. Clinical remission is typically described as a prolonged period without symptoms and with normal lung function, often measured using spirometry (FEV1 ≥ 80% predicted). Biological remission involves the absence of airway inflammation, which can be assessed using biomarkers such as fractional exhaled nitric oxide (FeNO) and sputum eosinophil counts. Despite these definitions, standardized criteria for remission are still lacking. The ATS/ERS Task Force on Severe Asthma has proposed a framework that includes both clinical and biological parameters, yet consensus on these criteria remains an ongoing challenge in the field [4-6].

Biomarkers identification and validation for predicting asthma exacerbation and remission

Asthma exacerbations pose significant challenges in clinical management, contributing to increased patient morbidity and healthcare costs. The identification and validation of biomarkers that predict asthma exacerbations are essential for enhancing disease management and tailoring treatment approaches. Biomarkers, encompassing proteins, gene expression profiles, or metabolites, provide insights into the pathophysiological mechanisms driving asthma. Technological advancements in omics, such as genomics, proteomics, and metabolomics, have facilitated the discovery of potential biomarkers linked to asthma exacerbation. For instance, periostin, a protein

indicative of airway inflammation, has emerged as a candidate biomarker. However, rigorous validation in diverse patient populations is crucial to establish their clinical utility.

In parallel, ongoing research is increasingly focusing on multi-omics approaches to identify biomarkers associated not only with exacerbations but also with asthma remission. By integrating genomics, proteomics, and metabolomics, researchers aim to uncover complex molecular signatures that distinguish between active disease and remission states. This holistic approach allows for a more comprehensive understanding of asthma's molecular underpinnings and the identification of novel biomarkers. For example, recent studies have employed integrative multi-omics analyses to explore the role of specific genetic variants, protein expression patterns, and metabolite profiles in asthma remission, paving the way for more personalized therapeutic strategies [8-15].

Mechanisms of remission (Table 1)

Understanding the mechanisms underlying asthma remission is crucial for developing targeted therapies. Possible factors contributing to remission include: 1. Immune modulation: Reduced airway inflammation and altered immune responses play a significant role. Studies have shown that regulatory T cells (Tregs) and Th2/Th17 cytokine profiles are critical in modulating inflammation. 2. Genetic factors: Certain genetic profiles may predispose individuals to remission. Polymorphisms in genes related to immune regulation (e.g. IL-10, TGF-β) and airway hyperresponsiveness have been implicated. 3. Environmental factors: Reduced exposure to allergens and pollutants can contribute to remission. Longitudinal studies indicate that environmental control measures, such as reducing indoor allergens, can improve asthma outcomes. 4. Medication adherence: Long-term adherence to anti-inflammatory medication, particularly inhaled corticosteroids (ICS), has been shown to enhance the likelihood of remission. ICS therapy reduces airway remodelling and inflammation, which are critical for achieving remission [16-21].

Factor	Impact on Remission
Age of Onset	Earlier onset, lower rates
Severity of Asthma	Mild asthma, higher rates
Genetics	Specific markers linked
Treatment Regimen	Consistent ICS use, higher rates

Table 1: *Factors influencing asthma remission.*

Predictors of remission (Table 2)

Several predictors of asthma remission have been identified through cohort studies and clinical trials: 1. Age of onset: Earlier onset of asthma is generally associated with lower remission rates. Children diagnosed before age 5 are less likely to achieve remission compared to those diagnosed later. 2. Severity: Mild asthma is more likely to remit than severe asthma. Patients with mild intermittent asthma have higher remission rates compared to those with persistent, severe asthma. 3. Genetics: Specific genetic markers, such as variations in the IL-13 and IL-4 receptor genes, have been linked to higher remission rates. Genetic studies continue to uncover potential biomarkers for predicting remission. 4. Treatment regimen: Consistent and early use of ICS is a strong predictor of remission. Patients who initiate ICS therapy soon after diagnosis are more likely to experience prolonged symptom-free periods [9-12].

Criteria	Description
Symptom-free Period	No symptoms for at least 12 months
Lung Function	Normal spirometry results (FEV1 > 80% predicted)
Inflammatory Markers	Absence of airway inflammation (e.g. FeNO)

Table 2: *Clinical and biological criteria for remission.*

Biomarkers identification and validation for predicting asthma exacerbation and remission

Asthma exacerbations pose significant challenges in clinical management, contributing to increased patient morbidity and healthcare costs. The identification and validation of biomarkers that predict asthma exacerbations are essential for enhancing disease management and tailoring treatment approaches. Biomarkers, encompassing proteins, gene expression profiles, or metabolites, provide insights into the pathophysiological mechanisms driving asthma. Technological advancements in omics, such as genomics, proteomics, and metabolomics, have facilitated the discovery of potential biomarkers linked to asthma exacerbation. For instance, periostin, a protein indicative of airway inflammation, has emerged as a candidate biomarker. However, rigorous validation in diverse patient populations is crucial to establish their clinical utility.

In parallel, ongoing research is increasingly focusing on multi-omics approaches to identify biomarkers associated not only with exacerbations but also with asthma remission. By integrating genomics, proteomics, and metabolomics, researchers aim to uncover complex molecular signatures that distinguish between active disease and remission states. This holistic approach allows for a more comprehensive understanding of asthma's molecular underpinnings and the identification of novel biomarkers. For example, recent studies have employed integrative multi-omics analyses to explore the role of specific genetic variants, protein expression patterns, and metabolite profiles in asthma remission, paving the way for more personalized therapeutic strategies.

Regulatory T cells, Th2/Th17, and Th1 profiles in asthma exacerbation: Endotypes and their roles

Asthma is a heterogeneous disease with various immune profiles, or endotypes, that drive inflammation and contribute to exacerbations. Regulatory T cells (Tregs), Th2, Th17, and Th1 cells are all implicated in the modulation of inflammation in asthma, and their roles can differ significantly across different asthma endotypes.

Th2-endotype asthma: The Th2 endotype is characterized by the production of cytokines such as IL-4, IL-5, and IL-13, which promote eosinophilic inflammation. This endotype is prevalent in allergic asthma and is associated with high levels of IgE, airway hyperresponsiveness, and a higher risk of exacerbations. Patients with a Th2-high endotype often respond well to corticosteroids and targeted biological therapies, such as anti-IL-5 and anti-IgE.

Th17-endotype asthma: The Th17 endotype is associated with the production of IL-17, which drives neutrophilic inflammation. Th17 cells contribute to a more severe form of asthma that is often resistant to corticosteroids and biological therapies targeting Th2 pathways. Patients with Th17-driven asthma may experience more frequent exacerbations, particularly in response to environmental triggers such as pollution or infections.

Th1-endotype asthma: Although less common, the Th1 endotype, characterized by the production of IFN-γ, is associated with a neutrophilic inflammatory response. This endotype is typically seen in patients with non-allergic asthma and may overlap with Th17-driven inflammation. Th1-driven asthma is often resistant to standard treatments and can lead to severe, uncontrolled asthma with frequent exacerbations.

Regulatory T cells (Tregs): Tregs play a crucial role in maintaining immune tolerance and preventing excessive inflammation. In asthma, the function and number of Tregs can be impaired, leading to uncontrolled inflammation and exacerbations. Tregs help suppress Th2 and Th17 responses, and their dysfunction is associated with more severe asthma phenotypes and exacerbations.

Asthma exacerbation endotypes

Asthma exacerbations can be driven by different immune endotypes, which are defined by the predominant inflammatory pathways involved:

- Eosinophilic (Th2-High) exacerbations: These exacerbations are characterized by elevated eosinophils and Th2 cytokines (IL-4, IL-5, IL-13). They are often triggered by allergens and are responsive to corticosteroids and Th2-targeted therapies.

Recent insights on asthma remission: A focus on immune modulation

Asthma remission, defined as the absence of symptoms and normalization of lung function without ongoing therapy, remains a critical goal in asthma management. Recent studies have focused on understanding the immune mechanisms that could facilitate remission, particularly through the modulation of immune profiles such as Th2, Th17, and regulatory T cells (Tregs). Here, we explore the most recent findings in this area, with a focus on publications from the last five years.

Th2/Th17 immune modulation: The interaction between Th2 and Th17 pathways is crucial in determining the chronicity or remission of asthma. Recent research has highlighted the role of targeting both Th2 and Th17 pathways to achieve long-term asthma control and potential remission. Modulation of these pathways may reduce airway inflammation and promote a more stable disease state.

Regulatory T cells (Tregs): Tregs are increasingly recognized for their role in maintaining immune tolerance and preventing asthma exacerbations. Recent studies have explored enhancing Treg function as a potential strategy for inducing remission. Approaches such as adoptive Treg therapy or the use of drugs that promote Treg activity are under investigation for their ability to sustain asthma remission.

Biomarker discovery for remission: Advances in omics technologies have facilitated the discovery of biomarkers that may predict or indicate remission. Recent publications have identified specific gene expression profiles, proteomic signatures, and metabolomic patterns associated with sustained remission, offering potential tools for personalized treatment strategies aimed at achieving long-term asthma control [13,14].

Clinical implications (Table 3)

Achieving remission can significantly improve quality of life and reduce healthcare costs. Pulmonologists should consider individualized treatment plans, focusing on early intervention and continuous monitoring to maximize the potential for remission. This approach includes: 1. Regular monitoring: Routine assessment of lung function and inflammatory markers to adjust treatment plans promptly. 2. Personalized medicine: Tailoring treatment based on genetic, environmental, and clinical factors to optimize outcomes. 3. Patient education: Educating patients about the importance of medication adherence and environmental control measures [15,16,21,22].

Predictor	Description
Age of Onset	Earlier onset linked to lower remission rates
Asthma Severity	Mild asthma more likely to remit
Genetic Factors	Specific polymorphisms associated with remission
Treatment Adherence	Early and constant ICS use increases likelihood

Table 3: *Predictors of asthma remission.*

Recent insights on asthma remission: A focus on immune modulation

Asthma remission, defined as the absence of symptoms and normalization of lung function without ongoing therapy, remains a critical goal in asthma management. Recent studies have focused on understanding the immune mechanisms that could facilitate remission, particularly through the modulation of immune profiles such as Th2, Th17, and regulatory T cells (Tregs). Here, we explore the most recent findings in this area, with a focus on publications from the last five years.

Th2/Th17 immune modulation: The interaction between Th2 and Th17 pathways is crucial in determining the chronicity or remission of asthma. Recent research has highlighted the role of targeting both Th2 and Th17 pathways to achieve long-term asthma control and potential remission. Modulation of these pathways may reduce airway inflammation and promote a more stable disease state.

Regulatory T cells (Tregs): Tregs are increasingly recognized for their role in maintaining immune tolerance and preventing asthma exacerbations. Recent studies have explored enhancing Treg function as a potential strategy for inducing remission. Approaches such as adoptive Treg therapy or the use of drugs that promote Treg activity are under investigation for their ability to sustain asthma remission.

Biomarker discovery for remission: Advances in omics technologies have facilitated the discovery of biomarkers that may predict or indicate remission. Recent publications have identified specific gene expression profiles, proteomic signatures, and metabolomic patterns associated with sustained remission, offering potential tools for personalized treatment strategies aimed at achieving long-term asthma control [23-33].

Conclusion

Asthma remission, while challenging, is a feasible goal for some patients. Further research is needed to refine remission criteria and identify reliable predictors. The integration of clinical and biological markers, along with personalized treatment strategies, holds promise for improving remission rates and overall asthma management.

The status of asthma remission is influenced by advances in personalized medicine, improved diagnostic tools, and enhanced therapeutic options. However, there remains a significant need for standardized remission criteria and better understanding of the underlying mechanisms. Future directions in asthma management aim to harness the potential of precision medicine and technological advancements: 1. Biomarkers: The identification and validation of biomarkers that predict remission are critical. Ongoing research is focused on multi-omics approaches, combining genomics, proteomics, and metabolomics to identify reliable biomarkers. 2. Biologics: The development of biologic therapies targeting specific pathways involved in asthma pathogenesis, such as IL-5, IL-4, and IL-13, has shown promise in achieving remission in severe asthma cases. Continued research in this area may expand the population of patients who can achieve remission. 3. AI-powered technologies: Artificial intelligence (AI) and machine learning (ML) are being increasingly utilized to predict asthma exacerbations, optimize treatment plans, and identify patients at risk of poor outcomes. AI algorithms can analyze large datasets, including electronic health records and genetic information, to develop personalized treatment strategies. 4. AI-powered future in asthma management: AI and ML are set to revolutionize asthma management by providing precise, data-driven insights. Future AI applications include: 1. Predictive analytics: Using patient data to predict asthma exacerbations and adjust treatment plans proactively. 2. Digital health platforms: Integrating wearable devices and mobile apps to monitor symptoms and medication adherence in real time. 3. Personalized medicine: Tailoring treatments based on AI analysis of genetic, environmental, and clinical data to optimize outcomes.

Asthma remission, while challenging, is a feasible goal for some patients. The integration of clinical and biological markers, along with personalized treatment strategies and AI-powered technologies, holds promise for improving remission rates and overall asthma management. Continued research and advancements in precision medicine and technology will be pivotal in making asthma remission an achievable target for a broader patient population.

Bibliography

1. Global Initiative for Asthma (GINA). “Global Strategy for Asthma Management and Prevention” (2022).
2. Boulet LP., *et al*. “Asthma and exercise-induced bronchoconstriction”. *Paediatric Respiratory Reviews* (2018).
3. Reddel HK., *et al*. “Asthma control and exacerbations”. *American Journal of Respiratory and Critical Care Medicine* (2009).

4. Wenzel SE. "Asthma phenotypes: the evolution from clinical to molecular approaches". *Nature Medicine* 18.5 (2012): 716-725.

5. Bateman ED., *et al*. "Overall asthma control: the relationship between current control and future risk". *The Journal of Allergy and Clinical Immunology* 125.3 (2010): 600-608.

6. Ducharme FM., *et al*. "Long-acting beta2-agonists versus inhaled corticosteroids". *Cochrane Database of Systematic Reviews* (2010).

7. Martinez FD. "Asthma endotypes: a new approach to classification". *Journal of Allergy and Clinical Immunology* (2011).

8. O'Byrne PM., *et al*. "Risk of asthma exacerbations in patients taking ICS/LABA". *The Lancet* (2020).

9. Bel EH. "Predicting exacerbations in asthma". *Current Opinion in Pulmonary Medicine* 19.1 (2013): 25-32.

10. Kuo CHS., *et al*. "T-helper cell type 2 (Th2) and Non-Th2 molecular phenotypes of asthma using sputum proteomic profiling and validation". *Journal of Allergy and Clinical Immunology* 135.6 (2015): 1534-1541.

11. Zetterquist W and Johannson SGO. "Biomarkers in asthma: An update". *Allergy, Asthma and Clinical Immunology* 16.1 (2020): 1-10.

12. Fahy JV. "Type 2 Inflammation in asthma-Present in most, absent in many". *Nature Reviews Immunology* 15.1 (2015): 57-65.

13. Bigler J., *et al*. "A severe asthma disease signature from gene expression profiling of peripheral blood from U-BIOPRED cohorts". *European Respiratory Journal* 49.5 (2017): 1602295.

14. Comhair SAA., *et al*. "Metabolomic endotype of asthma". *American Journal of Respiratory and Critical Care Medicine* 191.8 (2015): 759-772.

15. Woodruff PG., *et al*. "T-helper type 2-driven inflammation defines major subphenotypes of asthma". *American Journal of Respiratory and Critical Care Medicine* 180.5 (2009): 388-395.

16. Aboagye E and Bhavnani SK. "Integrative multi-omics approach to identify biomarkers of asthma remission". *BMC Medical Genomics* 11.2 (2018): 1-12.

17. Sorkness CA., *et al*. "Long-term evaluation of anti-inflammatory treatment". *Chest* (2007).

18. Busse WW., *et al*. "Mechanisms of asthma". *The New England Journal of Medicine* (2015).

19. Fitzpatrick AM., *et al*. "Severe asthma in childhood: insights into treatment". *The Lancet* (2016).

20. Holt PG., *et al*. "Role of immune factors in the pathogenesis of asthma". *Clinical and Experimental Allergy* (2011).

21. Holgate ST., *et al*. "Inflammatory basis of asthma". *Annals of Internal Medicine* (2007).

22. Jackson DJ., *et al*. "The role of viruses in asthma". *Clinical and Experimental Allergy* (2012).

23. Papadopoulos NG., *et al*. "Impact of infection on asthma". *Journal of Allergy and Clinical Immunology* (2012).

24. Schatz M., *et al*. "Asthma control test". *Journal of Allergy and Clinical Immunology* (2006).

25. Barnes PJ., *et al*. "Pathophysiology of asthma". *Annual Review of Physiology* (2016).

26. Bousquet J., *et al*. "Asthma research: current trends". *The Journal of Allergy and Clinical Immunology* (2009).

27. Humbert M., *et al*. "The future of asthma therapy". *The European Respiratory Journal* (2014).

28. Lemanske RF., *et al*. "Asthma prevention and treatment". *The Journal of Allergy and Clinical Immunology* (2010).

29. Lötvall J and Akdis CA. "Precision medicine in asthma: Towards a new understanding of asthma remission". *The Lancet Respiratory Medicine* 11.2 (2023): 111-120.

30. Uhl R., *et al*. "Biologic therapies and asthma remission: Current evidence and future directions". *Journal of Allergy and Clinical Immunology: In Practice* 10.1 (2022): 53-62.

31. Auvreau GM., *et al*. "The role of eosinophils in asthma remission: current evidence and future directions". *Allergy, Asthma and Clinical Immunology* 17.1 (2021): 1-12.

32. Alagappan VKT., *et al*. "Understanding asthma remission: The role of regulatory T cells and immune modulation". *Allergy* 75.8 (2020): 1987-1999.

33. Hung KF and Wenzel SE. "Asthma phenotypes and endotypes: Moving toward precision medicine in asthma remission". *European Respiratory Journal* 59.4 (2022): 2101855.

Volume 13 Issue 10 October 2024